Navigation Links
Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and TLR9
Date:11/26/2007

Animal Model Shows Disease Progression Can Be Prevented

BERKELEY, Calif., Nov. 26 /PRNewswire-FirstCall/ -- In a paper appearing online in the December issue of The European Journal of Immunology (Vol. 37, Issue 12), Dynavax scientists report the results of studies made possible under a grant from the Alliance for Lupus Research (ALR). In the article entitled, "Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms", the data show that Dynavax's proprietary IRS 954, a specific inhibitor of two Toll-like receptors, TLR7 and TLR9, can prevent progression of disease when injected in the lupus prone (NZBxNZW)F1 mice. The authors observed a significant reduction of serum levels of nucleic acid specific autoantibodies, the hallmark of systemic lupus erythematosus. IRS 954 treatment also resulted in decreased proteinuria, glomerulonephritis and end-organ damage and increased survival, compared to untreated mice. A copy of the article is posted on http://www.dynavax.com/publications.htm.

According to Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer, "These results show that the previously reported ability of IRS 954 to block IFN-alpha translates into reduced symptoms in an animal model of lupus. The data support our hypothesis that blocking both TLR7 and TLR9 in B cells and in human plasmacytoid dendritic cells is a promising new approach for the treatment of lupus. The ability of IRS 954 to specifically intervene in the inappropriate immune signaling cascade that leads to autoimmunity may have application for other autoimmune diseases as well."

IRS 954 represents a novel class of oligonucleotides, named immunoregulatory sequences (IRS), that specifically inhibit the TLR-induced inflammatory response implicated in disease progression in lupus. In 2005, the Alliance for Lupus Research awarded to Dynavax a $500,000 grant to explore new treatment approaches for systemic lupus erythematosus based on the company's novel IRS technology. The grant was the first time ALR had provided funding to a private company.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAVTM, a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBATM, a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our preclinical hepatitis C therapeutic program, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.

This press release contains forward-looking statements that are subject to a number of risks and uncertainties, including statements about the potential for our IRS as an approach for the treatment of lupus and multiple autoimmune diseases. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including difficulties or delays in research and development and other risks detailed in the "Risk Factors" section of our Quarterly Report on Form 10-Q. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.


'/>"/>
SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. Dynavax to Present at UBS 2007 Global Life Sciences Conference
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Dovetail Genomics™ LLC today announced that it has ... planned metagenomic genome assembly service. Richard Green , ... method in a talk on Friday, February 12 at ... in Orlando, Fla. ... difficult. Using its proprietary Chicago ™ ...
(Date:2/11/2016)... Buffalo, New York (PRWEB) , ... February 11, ... ... and analytical instruments for more than 150 years, continues today to pursue the ... to its line of analytical instruments: the AR9 Refractometer and the AR5 Refractometer. ...
(Date:2/10/2016)... Inc. (NYSE: BIOA ), a leader in renewable ... Ltd., its partner in the Sarnia ... CDN$25 million in the joint venture for 10% of ...  Mitsui will also play a stronger role in the ... , providing dedicated resources alongside BioAmber,s commercial team. ...
(Date:2/10/2016)... -- NX Prenatal Inc., a US based molecular ... early warning of adverse pregnancy outcomes, announced today ... Dr. Thomas McElrath of Brigham & ... (SMFM) annual meeting held in Atlanta ... presentation reported initial positive top-line results regarding the ...
Breaking Biology Technology:
(Date:2/9/2016)... AWRE ), a leading supplier of biometrics software and services, ... December 31, 2015.  --> --> ... an increase of 61% compared to $4.3 million in the same ... was $2.6 million compared to $0.2 million in the fourth quarter ... Higher revenue and operating income in the fourth quarter of this ...
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
Breaking Biology News(10 mins):